Original (for SUBMISSION)

8	For receiving Office use only		
\$ -\$	international Application No.		
Ø-2	International Filing Date		
6-3	Name of receiving Office and "PCT International Application"		
8-4-1 8-4-1	Form PCTMC(101 PCT Request Prepared Lising	PCT-SAFE (EASY mode) Version 3.50 (Build 0002.163)	
\$-\$	Patition		
	The undersigned requests that the present international application be processed according to the Patent Cooperation Treety		
8-8	Receiving Office (specified by the applicant)	European Patent Office (EPO) (RO/EP)	
Q-7	Applicant's or agent's file reference	WAR/PB60596	
\$	Title of invention	NOVEL USE	
18	Applicant		
15-4	This person is	applicant only	
8-2	Applicant for	all designated States except US	
84	Name	SMITHWLINE BEECHAN CORPORATION	
8-5	Address	One Franklin Plass, P.O. Box 7929 Philadelphia, Pennsylvania 19101 United States of America	
8-8	State of nationality	vs	
8.7	State of residence	vs	
8-8	Temphone No.	020 8047 5000	
8.8	Facisimile No.	020 8047 6894	

Original (for SUBMISSION)

386-1	Applicant and/or inventor	
1044	This person is	applicant and inventor
1874-5	Applicant for	US only
181-1-4	Name (LAST, First)	DEELY, Judith, Bramel
¥4-1-8	Address	GlaxoSmithKline Five Moore Drive Research Triangle Park Durham, North Carolina 27709 United States of America
#14	State of nationality	US
38-5-7	State of residence	US
\$81-22	Applicant and/or inventor	
38-2/1	This person is	applicant and inventor
88-2-2	Applicant for	US only
88- 2-4	Name (LAST, First)	GERRARD, Philip, Alan
88-2-5	Address	GlaxoSmithEline S.p.A. Via Alessandro Fleming, 2 I-37135 Verona Italy
88-2-6	State of nationality	GB
88-2-7	State of residence	1.2
81-3	Applicant endier inventor	
88-3-1	This person is	applicant and inventor
88-3-2	Applicant for	US only
86-3-4	Name (LAST, First)	GOODALE, Elizabeth, Parsons
M-3-5	Address	GlaxoSmithKline Five Moore Drive Research Triangle Park Durham, North Carolina 27709 United States of America
81-3-6	State of nationality	us
33-3-7	State of residence	us

Original (for SUBMISSION)

88-4	Applicant and/or Inventor	
35-4-3	This person is	applicant and inventor
85-4-2	Applicant for	
88-4-4	Name (LAST, First)	US only
88-4-8	Address	LEARNED-COUGHLIN, Susan, Maria
88999	Acaress	GlaxoSmithKline
		Five Moore Drive Research Triangle Park
		Durham, North Carolina 27709
		United States of America
8846	State of nationality	vs
88-4-7	State of residence	vs
88-S	Applicant and/or inventor	
11564	This person is	applicant and inventor
88-6-5	Applicant for	us only
188-8-4	Name (LAST, First)	NOBBS, Malcolm, Stuart
88-5	Address	GlaxoSmithKline
		New Frontiers Science Park South
		Third Avenue
		Harlow
		Essex
		CM19 SAW
88-5-6	State of nationally	United Kingdom
88-8-7	State of ossidence	GB
50-5-7 50-4		GE
355-3	Agent or common representative; or address for correspondence	
	The person identified below is hereby!	agent
	has been appointed to act on behalf of	off are c
	the applicant(s) before the competent international Authorities as:	
17-4-1	Name (LAST, First)	REED, Michael
8442	Address	GlaxoSmithKline
		C.I.P (CN925.1)
		980 Great West Noad
		Brentford
		Middlesex
		TWE 9GS
87-4-3	Vellaphone hip	United Kingdom
	,	020 8047 4455
88-8-4	Facsimile No.	020 8047 6894

4/5 . . . * Original (for SUBMISSION.)

¥	DESIGNATIONS		
X-18	The filing of this request constitutes		
	under Rule 4.9(a), the designation of		
	all Contracting States bound by the		
	PCT on the international filing date.		
	for the grant of every kind of		
	protection available and, where		
	applicable, for the grant of both		
	regional and netional patents.		
WH	Priority claim of earlier national		
	application		
147.27	Fling date	27 November 2003 (27)	.11.2003)
W4-2	Manber	0327619.3	
VI-1-3	Country	GB	
V8-1	International Searching Authority	European Patent Offic	ce (EPO) (ISA/EP)
	Chosen	more planted a property	non-francisch Zoomenh 2002 h
VIII	Declarations	Number of declarations	
VSM	Declaration as to the identity of the		······································
	inventor	.	
V88-2	Declaration as to the applicant's writt	*	
	Sement, as at the internetional filing date,		
	to apply for and be granted a patent		
V88-3	Coclaration as to the applicant's	<u></u>	
	antitioment, as at the international fling		
	date, to claim the priority of the earlier application		
V88-4	Declaration of inventorable loosy for the		
	corpones of the designation of the United States of America)		
VSES			
2000	Declaration as to non-prejudicial disclosures or exceptions to lack of	! **	
	contract to entertain to some or		
XX	Check list	mumber of alwests	electronic flis(s) attached
(X-1	Request (including declaration sheets)	\$	<i>*</i>
0X-2	Description	14	······································
06-3			***************************************
(X-4		<u> </u>	
,,,,	Abstract	1	
08-6	Crowings	3	~
IX-7	TOTAL.	24	
	Accompanying items	paper document(s) attached	electronic file(s) attached
(X-8	Fee celculation sheet	✓	*
X-13	Pritrily decuments	Item(s) VI-1	
(X-17	PCT-SAFE physical media	*	<i>\</i>
X-18	Figure of the drawings which should		
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	accompany the abstract		
1X-20	Language of filing of the informational application	English	

Original (for **SUBMISSION**)

X	Signature of applicant, agent or common representative	144144
X-1-1	Name (LAST, First)	MEED, Michael
X-1-2	Mame of signatory	
X-4-2	Capacity	

FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported international application	
10-2	Drawings:	
10-2-1	Received	
18-2-2	Not received	
19-3	Corrected date of actual receipt due to later but limely received papers or drawings completing the purported international application	
10-4	Date of limely receipt of the required corrections under PCT Article 11(3)	
10-8	international Searching Authority	ISA/EP
13-6	Transmittal of search copy delayed until search fee is paid	

FOR INTERNATIONAL BUREAU USE ONLY

munu		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3 8.4	 Date of receipt of the record copy by 	§
	the international Sureau	
	tana tananatananan tahuana	\$
-33333333333	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	A*************************************